The complex journey of targeting RAS in oncology
Abstract Given the prevalence of RAS mutations in various cancers, personalized therapeutic approaches, guided by molecular markers, are essential. Farnesyltransferase inhibitors (FTIs) have emerged as potential therapeutic options; however, they also face obstacles such as toxicity and limited effi...
Αποθηκεύτηκε σε:
| Κύριοι συγγραφείς: | , , , , , , |
|---|---|
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
BMC
2025-07-01
|
| Σειρά: | BMC Cancer |
| Θέματα: | |
| Διαθέσιμο Online: | https://doi.org/10.1186/s12885-025-14033-y |
| Ετικέτες: |
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|